Commercial strategy shouldn't be an afterthought in Biotech, it's the base every smart biotech builds on from day one.

For early-stage CEOs, the companies attracting serious capital in 2026 aren't just the ones with the strongest science. They're the ones who can demonstrate a credible commercial narrative long before they reach Series A or B. Waiting until later to think about commercialisation means losing the window where science and strategy can't afford to ignore.

View more blog posts

AI in Regulatory Affairs: What our Panel Conversations Are Actually Revealing

On a Panel at Pharma Tech Summit 2026, we discussed multiple perspectives around AI usage in biotech. Here's what we learned.

Building Biotech: How Nigeria can become the Vaccine Powerhouse in Africa

Lee Smith and Oyeronke Oyebanji sat down with BioProcess Insider to discuss the vaccine development and delivery practices in Nigeria: the good, the bad, and the path forward.

Live Attenuated Viral Vaccines Advancements

Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe.

Hope for Chlamydia STI Vaccine After Promising Initial Results

A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials.

GreyRigge Associates partners with NG Bio to accelerate VC investment

NG Bio and GreyRigge Associates Announce Strategic Partnership to Advance Biotech Innovation

Gene Therapy for Rare Disorders

Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy.

CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development

CEPI awards US$21 million to Themis Bioscience.

Greyrigge Associates partner with SciPot Consultancy

GreyRigge Associates partner with Pharma and Biotech consultancy: SciPot Consultancy

Building Biotech: Being ready for AI

AI is advancing faster than biotech's frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee and Andrew have documented what they think it will take for biotech to effectively integrate AI at the pace innovation now takes place.

010

Building Biotech: How COVID-19 changed development forever

The COVID-19 pandemic transformed vaccine development by compressing timelines from decades to months, proving that rapid innovation is possible through parallel development, adaptive regulation, and unprecedented global equity.

011

Building Biotech: Animal Models and Beyond - What's Next?

Animal models have long underpinned vaccine development by enabling preclinical evaluation of immunogenicity, efficacy, safety, and dose selection, and they remain integral to regulatory submissions and certain approval pathways such as the FDA Animal Rule.

012